A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma

Author:

Patel Shetal A.12ORCID,Gibson Michael K.3,Deal Allison2,Sheth Siddharth12ORCID,Heiling Hillary2,Johnson Steven M.4ORCID,Douglas Kathe2ORCID,Flores Melissa2,Blumberg Jeffrey5,Lumley Catherine5,Yarbrough Wendell G.5,Shen Colette6,Chera Bhishamjit S.7,Bauman Jessica R.8,Hackman Trevor5,Weiss Jared1ORCID

Affiliation:

1. Division of Medical Oncology Department of Medicine The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

2. Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

3. Division of Hematology/Oncology Department of Medicine Vanderbilt University Medical Center and the Vanderbilt‐Ingram Cancer Center Nashville Tennessee USA

4. Department of Pathology and Laboratory Medicine The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

5. Department Otolaryngology‐Head and Neck Surgery The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

6. Department of Radiation Oncology The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

7. Department of Radiation Oncology Medical University of South Carolina Charleston South Carolina USA

8. Department of Hematology/Oncology Fox Chase Cancer Center Philadelphia Pennsylvania USA

Abstract

AbstractBackgroundPatients with locally advanced head and neck squamous cell cancer (HNSCC) are treated with surgery followed by adjuvant (chemo) radiotherapy or definitive chemoradiation, but recurrence rates are high. Immune checkpoint blockade improves survival in patients with recurrent/metastatic HNSCC; however, the role of chemo‐immunotherapy in the curative setting is not established.MethodsThis phase 2, single‐arm, multicenter study evaluated neoadjuvant chemo‐immunotherapy with carboplatin, nab‐paclitaxel, and durvalumab in patients with resectable locally advanced HNSCC. The primary end point was a hypothesized pathologic complete response rate of 50%. After chemo‐immunotherapy and surgical resection, patients received study‐defined, pathologic risk adapted adjuvant therapy consisting of either durvalumab alone (low risk), involved field radiation plus weekly cisplatin and durvalumab (intermediate risk), or standard chemoradiation plus durvalumab (high risk).ResultsBetween December 2017 and November 2021, 39 subjects were enrolled at three centers. Oral cavity was the most common primary site (69%). A total of 35 of 39 subjects underwent planned surgical resection; one subject had a delay in surgery due to treatment‐related toxicity. The most common treatment‐related adverse events were cytopenias, fatigue, and nausea. Post treatment imaging demonstrated an objective response rate of 57%. Pathologic complete response and major pathologic response were achieved in 29% and 49% of subjects who underwent planned surgery, respectively. The 1‐year progression‐free survival was 83.8% (95% confidence interval, 67.4%–92.4%).ConclusionsNeoadjuvant carboplatin, nab‐paclitaxel, and durvalumab before surgical resection of HNSCC were safe and feasible. Although the primary end point was not met, encouraging rates of pathologic complete response and clinical to pathologic downstaging were observed.

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3